The wider-than-expected net loss is a near-term headwind, but the 25% QoQ IBTROZI revenue growth and strong commercial positioning support the bull case. Monitor the January 4, 2027 sNDA action date for label expansion and upcoming safusidenib Phase 3 data for the next major catalysts.
Price Chart
Executive Summary
Nuvation Bio reported Q2 2026 total revenue of $31.7M, including $23.2M in IBTROZI product revenue (25% QoQ growth), but posted a GAAP net loss of $62.8M ($-0.18/share), wider than the $-0.12 consensus estimate. The company highlighted strong commercial momentum for IBTROZI as the most prescribed ROS1 TKI in new patient starts, positive safusidenib Phase 2 data, and a strengthened balance sheet from a $279.1M convertible notes offering. The wider-than-expected loss and lack of formal guidance temper the positive commercial and pipeline updates.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue of $31.7M vs $4.8M YoY, including $23.2M IBTROZI product revenue (25% QoQ growth)
- GAAP net loss of $62.8M ($-0.18/share) vs consensus $-0.12; wider loss driven by $9.5M debt extinguishment loss and higher SG&A
- Cash, equivalents, and marketable securities of $661.0M at June 30, 2026; additional $36.5M from July overallotment
- IBTROZI became the most prescribed ROS1 TKI in both first-line and overall new patient starts in 2026 (IQVIA data)
- Announced positive updated Phase 2 safusidenib data (51.9% ORR, median PFS not reached) and initiated two new studies
- Completed $279.1M 0.75% Convertible Senior Notes offering in July 2026 with capped calls at $10.4580/share
Financial Impact
Net loss of $62.8M on $31.7M revenue; EPS miss of $0.06 vs consensus
Risk Factors
- Wider-than-expected net loss and EPS miss could pressure near-term sentiment
- Convertible notes add $242.6M in debt, increasing interest expense and potential dilution if converted
- Competitive landscape for ROS1+ NSCLC (entrectinib, crizotinib) and IDH1-mutant glioma (vorasidenib) remains intense
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336751 |
| Document: d261840d8k.htm | 0001193125-26-336751 |
| Document: 0001193125-26-336751-index-headers.html | 0001193125-26-336751 |
| Document: 0001193125-26-336751-index.html | 0001193125-26-336751 |
| Document: 0001193125-26-336751.txt | 0001193125-26-336751 |
| 8-K Data (Synthetic) | 0001193125-26-336751 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | Press Release | $4.70 | awaiting T+60 | — | $4.57 (−2.87%) |
Aug 6, 2026 11w ago | 8-K | $6.11 | awaiting T+60 | — | $4.57 (−25.29%) |
Jun 26, 2026 17w ago | 424B5 | $5.61 $6.10 | ▼ −8.73% | ▼ −4.35% | $4.57 (+18.63%) |
Jun 23, 2026 17w ago | 144 | $6.46 $6.07 | ▲ +6.04% | ▲ +8.88% | $4.57 (+29.33%) |
Jun 23, 2026 17w ago | 144 | $6.46 $6.07 | ▼ −6.04% | ▼ −8.88% | $4.57 (−29.33%) |
May 4, 2026 24w ago | 8-K | $4.83 $6.70 | ▲ +38.72% | ▲ +35.98% | $4.57 (−5.49%) |
Apr 21, 2026 26w ago | DEFA14A | $5.11 $5.64 | ▲ +10.37% | ▲ +3.47% | $4.57 (−10.67%) |
Apr 17, 2026 27w ago | 144 | $5.12 $5.90 | ▲ +15.23% | ▲ +8.46% | $4.57 (−10.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers